Zhejiang Wolwo Biotech Co., Ltd. (Wolwo Pharma) recently downloaded a Clinical Trial Approval Notice from the government service portal of the National Medical Products Administration (NMPA), granting approval for the clinical trial application of its self-developed S01D tablet to conduct trials for the treatment of adult drug-resistant pulmonary tuberculosis.
According to the announcement, S01D tablet is classified as a Class 1 chemical drug in tablet form with anti-Mycobacterium tuberculosis activity, intended for adult patients with drug-resistant pulmonary tuberculosis. As of the announcement date, no identical chemical drug has been approved in China or abroad.
Tuberculosis treatment currently relies mainly on multidrug combination regimens, while drug-resistant tuberculosis has long faced the clinical challenges of lengthy treatment courses, poor efficacy and severe adverse reactions. As a new molecular entity with a novel mechanism of action, S01D showed superior anti-tuberculosis activity in nonclinical studies.
The company is a biopharmaceutical enterprise specializing in the R&D, production and sale of diagnostic and therapeutic products for allergic diseases, and is gradually expanding into stem cell drugs and natural drugs (anti-drug-resistant antibiotics). It is preparing the Phase I clinical trial of S01D; subsequent Phase II and Phase III trials and marketing authorization are still required, with considerable uncertainty in the R&D outcomes.

Source: https://stock.stockstar.com/notice/SN2026102100000384.shtml